TEL/AML1 and immunoreceptor gene rearrangements—which comes first?

Zuna, Jan; Krejci, Ondrej; Madzo, Jozef; Fronkova, Eva; Sramkova, Lucie; Hrusak, Ondrej; Kalina, Tomas; Vaskova, Martina; Stary, Jan; Trka, Jan; The Czech Paediatric Haematology Working Group (CPH),

doi:10.1016/j.leukres.2004.11.007

« Previous Next »Leukemia Research
Volume 29, Issue 6 , Pages 633-639, June 2005

TEL/AML1 and immunoreceptor gene rearrangements—which comes first?

Jan Zuna
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles University Prague, V Uvalu 84, 150 06 Prague 5, Czech Republic
- Corresponding author. Tel.: +420 22443 6580; fax: +420 22443 6521.
Ondrej Krejci
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles University Prague, V Uvalu 84, 150 06 Prague 5, Czech Republic
Jozef Madzo
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles University Prague, V Uvalu 84, 150 06 Prague 5, Czech Republic
Eva Fronkova
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles University Prague, V Uvalu 84, 150 06 Prague 5, Czech Republic
Lucie Sramkova
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles University Prague, V Uvalu 84, 150 06 Prague 5, Czech Republic
Ondrej Hrusak
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Immunology, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
Tomas Kalina
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Immunology, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
Martina Vaskova
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Immunology, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
Jan Stary
- Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles University Prague, V Uvalu 84, 150 06 Prague 5, Czech Republic
Jan Trka
- CLIP - Childhood Leukaemia Investigation Prague, 2nd Medical School, Charles University Prague, V Uvalu 84, Prague, Czech Republic
- Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles University Prague, V Uvalu 84, 150 06 Prague 5, Czech Republic
The Czech Paediatric Haematology Working Group (CPH)

Received 10 August 2004; accepted 23 November 2004.

Abstract

TEL/AML1 fusion gene is present in 20–25% of childhood acute lymphoblastic leukaemias. In order to unravel at which stage of B-cell precursor development the fusion is originated, we analysed frequency and pattern of immunoreceptor (immunoglobulin and T-cell receptor) gene rearrangements in 47 TEL/AML1-positive and 43 TEL/AML1-negative cases of the same CD10+ immunophenotype. Moreover, we compared corresponding immunoreceptor gene rearrangements in 11 cases of TEL/AML1-positive leukaemia at diagnosis and relapse. More mature immunogenotype of TEL/AML1-positive cases and changes in 37% of rearrangements between diagnosis and relapse suggest that in most cases the TEL/AML1 fusion is formed during immunoreceptor gene rearrangement process.

Keywords: Acute lymphoblastic leukaemia, TEL/AML1, Immunoglobulin, T-cell receptor, Rearrangement, Relapse